If you have been reading about Metabolite and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Food preservation includes processes that make food more resistant to microorganism growth and slow the oxidation of fats. This slows down the decomposition and rancidification process. Food preservation may also include processes that inhibit visual deterioration, such as the enzymatic browning reaction in apples after they are cut during food preparation. By preserving food, food waste can be reduced, which is an important way to decrease production costs and increase the efficiency of food systems, improve food security and nutrition and contribute towards environmental sustainability. For instance, it can reduce the environmental impact of food production. Many processes designed to preserve food involve more than one food preservation method. Preserving fruit by turning it into jam, for example, involves boiling (to reduce the fruit's moisture content and to kill bacteria, etc.), sugaring (to prevent their re-growth) and sealing within an airtight jar (to prevent recontamination). Different food preservation methods have different impacts on the quality of the food and food systems. Some traditional methods of preserving food have been shown to have a lower energy input and carbon footprint compared to modern methods. Some methods of food preservation are also known to create carcinogens.
In 1966 the Johns Hopkins Gender Identity Clinic opened; it was one of the first in the US to provide care for transgender individuals, including hormone replacement therapy, surgery, psychological counseling, and other gender affirmative healthcare. The clinic required patients before a gender affirmation surgery to go through a program called "Real Life Test". The Real Life Test was a program where before a gender affirming surgery the patient was required to live with their desired gender role. In 1979 the clinic was closed by the newly appointed director of psychiatry Paul R. McHugh.
=== Residential life === The university offers on and off campus housing options including multiple dining services catering to students of various backgrounds and needs. University resources and services available for all students include the student center, university gym, food resource center, health center, counseling center, memorial chapel and youth ministry, and career development centers.
Sources: en.wikipedia.org
Although the concern over the effects began to grow, the violent depictions remained the same. In a 1989 longitudinal study conducted by the Cultural Indicators Project, they analyzed the portrayal of mentally ill characters on 1,215 television programs between 1969 and 1985. They found that 3 out of 4 characters were involved in violent situations, either becoming victims of violence or perpetrating it. In addition to the mentally ill characters having violent tendencies, they also were distancing themselves from loved ones, and often did not work. Finally, nearly 50 years after one of the inaugural studies that analyzed the overuse of mentally ill, violent characters in media, the misconception persists, even into the 21st century. Diefenbach and West conducted a cultivation study that examined 84 hours of prime-time television among major networks in April 2003. They found that mentally ill characters on television were much more likely to commit violent crimes than real-world statistics. Only 4% of people with mental illnesses in the real world are characterized as violent, while 37% of mentally ill characters on television are portrayed as violent.
== Career == In 2001, Nigam founded the Swansea University Maggot Research Group, of which she is a director. The group focuses on therapeutic applications of the medicinal maggot Lucilia sericata. She then became an associate professor at Swansea University. In 2018, Nigam was promoted to professor which included a move from the research to the innovation and engagement strand. Nigam fulfills many roles outside of her permanent academic position. In 2007, she became a member of the Welsh Wound Network group, an enterprise which aims to support the clinical development of wound healing science. In April 2014, she was an elected participant of the Welsh Crucible Programme. Nigam is an elected Fellow of the Royal Entomological Society (FRES).
=== Magic numbers === As early as 1914, the possible existence of superheavy elements with atomic numbers well beyond that of uranium—then the heaviest known element—was suggested, when German physicist Richard Swinne proposed that superheavy elements around Z = 108 were a source of radiation in cosmic rays. Although he did not make any definitive observations, he hypothesized in 1931 that transuranium elements around Z = 100 or Z = 108 may be relatively long-lived and possibly exist in nature. In 1955, American physicist John Archibald Wheeler also proposed the existence of these elements; he is credited with the first usage of the term "superheavy element" in a 1958 paper published with Frederick Werner. This idea did not attract wide interest until a decade later, after improvements in the nuclear shell model. In this model, the atomic nucleus is built up in "shells", analogous to electron shells in atoms. Independently of each other, neutrons and protons have energy levels that are normally close together, but after a given shell is filled, it takes substantially more energy to start filling the next. Thus, the binding energy per nucleon reaches a local maximum and nuclei with filled shells are more stable than those without. This theory of a nuclear shell model originates in the 1930s, but it was not until 1949 that German physicists Maria Goeppert Mayer and Johannes Hans Daniel Jensen et al. independently devised the correct formulation. The numbers of nucleons for which shells are filled are called magic numbers.
There are actually two very closely related compounds commonly referred to as eosin. Most often used is in histology is eosin Y, which is a tetra-bromo derivative of fluorescein and has a very slightly yellowish cast. It is also known as eosin Y ws, eosin yellowish, Acid Red 87, C.I. 45380, bromoeosine, bromofluoresceic acid, and D&C Red No. 22. The other eosin compound is eosin B, which is a dibromo derivative and has a very faint bluish cast. It is also known as eosin bluish, Acid Red 91, C.I. 45400, Saffrosine, Eosin Scarlet, and imperial red. The two dyes are interchangeable, and the use of one or the other is a matter of preference and tradition. Food dye tetraiodofluorescein was historically known as Bluish Eosine, Eosin J or iodo-eosine but is now called erythrosine or Red 3.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.